DEXCOM, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 124.3 USD | -9.91% |
|
-4.87% | +0.20% |
| 04-26 | Wall Street: the worst week of 2024 is followed by the best | CF |
| 04-26 | Morgan Stanley Adjusts DexCom's Price Target to $132 From $122 | MT |
| Sales 2024 * | 4.33B 347B | Sales 2025 * | 5.16B 413B | Capitalization | 49.45B 3,958B |
|---|---|---|---|---|---|
| Net income 2024 * | 708M 56.68B | Net income 2025 * | 895M 71.65B | EV / Sales 2024 * | 11.8 x |
| Net Debt 2024 * | 1.52B 122B | Net Debt 2025 * | 839M 67.2B | EV / Sales 2025 * | 9.74 x |
| P/E ratio 2024 * |
71.3
x | P/E ratio 2025 * |
57.3
x | Employees | 9,550 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.23% |
More Fundamentals
* Assessed data
More news
Latest transcript on DexCom, Inc.
More recommendations
More press releases
More news
| 1 day | -9.91% | ||
| 1 week | -4.87% | ||
| Current month | -10.35% | ||
| 1 month | -10.85% | ||
| 3 months | +1.95% | ||
| 6 months | +39.25% | ||
| Current year | +0.20% |
1 week
124.08
139.24
1 month
124.08141.99
Current year
113.05142.00
1 year
74.75142.00
3 years
66.89164.86
5 years
28.41164.86
10 years
7.02164.86
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Sayer
CEO | Chief Executive Officer | 66 | 31/10/07 |
Jereme Sylvain
DFI | Director of Finance/CFO | 44 | 31/08/18 |
| Chief Tech/Sci/R&D Officer | 47 | 30/09/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nick Augustinos
BRD | Director/Board Member | 65 | 19/11/09 |
Mark Foletta
BRD | Director/Board Member | 63 | 18/11/14 |
Eric Topol
BRD | Director/Board Member | 69 | 08/07/09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.46% | 18 M€ | +3.79% | - | |
| 1.04% | 16 M€ | -8.49% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 124.3 | -9.91% | 8,578,184 |
| 25/04/24 | 138 | +0.10% | 4,203,199 |
| 24/04/24 | 137.9 | +2.89% | 3,238,221 |
| 23/04/24 | 134 | +1.89% | 2,014,910 |
| 22/04/24 | 131.5 | +0.62% | 2,110,326 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals.
The United States accounts for 72.5% of net sales.
Calendar
24/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
124.3
USD
Average target price
150.4
USD
Spread / Average Target
+20.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.20% | 49.45B | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B | |
| -1.93% | 24.52B |
- Stock Market
- Equities
- DXCM Stock
